<DOC>
	<DOC>NCT01965145</DOC>
	<brief_summary>The objective of this study is to demonstrate the superiority of gevokizumab as compared to placebo on top of current standard of care in reducing the risk of Behçet's disease uveitis exacerbations</brief_summary>
	<brief_title>Efficacy of Gevokizumab in the Treatment of Patients With Behçet's Disease Uveitis (EYEGUARD™-B)</brief_title>
	<detailed_description>A randomized, double-masked, placebo-controlled study of the efficacy of gevokizumab in the treatment of patients with Behçet's disease uveitis</detailed_description>
	<mesh_term>Uveitis</mesh_term>
	<mesh_term>Behcet Syndrome</mesh_term>
	<mesh_term>Pharmaceutical Solutions</mesh_term>
	<criteria>Behçet's disease diagnosis fulfilling the International Study Group Classification Criteria. History of Behçet's disease uveitis with ocular involvement of the posterior segment. Patients with a stable background treatment of oral corticosteroid and at least one immunosuppressive drug. Male or female, age ≥18 (or legal age of majority in the country) at selection For subjects with reproductive potential, a willingness to use highly effective contraceptive measures Infectious uveitis, uveitis due to causes other than Behçet's disease. Monocular vision Presence of severe cataract or severe posterior capsular opacification. Contraindication to mydriasis or presence of posterior synechiae. Active TB disease. History of severe allergic or anaphylactic reactions to monoclonal antibodies History of malignancy within 5 years prior to Selection. Other protocoldefined inclusion/exclusion criteria may apply</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2015</verification_date>
</DOC>